Healthcare in Thoughts from the Centre
- Select a blog category
By Sheryl Jacobson, US Consulting Medtech leader, Deloitte Consulting, LLP
In 2018, our report Medtech and the Internet of Medical Things (IOMT) highlighted how major advances in technology were driving innovation in medtech, leading to the development of the IoMT – a digitally connected infrastructure of medical devices, software applications and health systems and services. We examined how the IoMT was transforming medtech’s role in health care and what medtech companies needed to do to get digital transformation right. In May 2023, our colleagues in the US Center for Health Solutions surveyed 100 executives from large medtech companies across the United States, Europe, and Asia to understand how medtech companies are employing digital technologies to grow, innovate, and develop a competitive edge. This week’s blog which first appeared as a Center for Health Solution’s Health Forward blog, explores key findings from this survey including the maturity of digital transformation, the role of partnerships in accelerating the transformation and strategies to execute this long-term plan.
By Emily May, Manager, Deloitte Centre for Health Solutions
A wide body of research demonstrates that vaccines saves lives and are a highly cost-effective public health intervention that protects people’s health, improves a country’s resilience and productivity, and ensures a safer, healthier world.1 Like all medicines, vaccines are not completely risk-free, but rigorous clinical research and development and continued surveillance, helps ensure vaccines are safe for the vast majority of people.2 The COVID-19 pandemic ushered in a new era for vaccines, with scientific breakthroughs and novel technologies, like mRNA vaccines, expediting the development and delivery of preventative treatments. However, it also increased vaccine hesitancy, undermining public confidence in, and uptake of, vaccines. This has led to a resurgence of diseases that were on the verge of being eradicated.3 This week’s blog explores the impact of vaccinations on public health and strategies for effective immunisation programmes.
By Dr Márcia Costa, manager at Deloitte Centre for Health Solutions
Every year January is designated as Cervical Cancer Awareness Month and is followed on February 4th, by World Cancer Day which is aimed at raising cancer awareness and incentivising action for a cancer-free world. This blog, spurred by the similar aims of these two campaigns, explores the extent and causes of inequities in eliminating cervical cancer, where the availability of effective vaccines and cervical screening programmes makes elimination entirely feasible. Today, however, large inequities exist with some 90 per cent of cervical cancer cases occurring in low- and middle-income countries (LMICs), where few women have access to vaccines and 64–67 per cent have never been screened.1 Even in high-income countries, inequities exist between socio-economic groups. We believe that reducing health inequities in cervical cancer prevention could help provide a blueprint for reducing inequities in the treatment and outcomes for other cancers.
By Karen Taylor, Director of the Deloitte Centre for Health Solutions
Last week Deloitte’s Director of Public Sector Research, together with the Director at Reform, published their findings from the 12th edition of Deloitte and Reform’s influential annual State of the State report. The report again blends two sets of insights: a view from the people who depend on the state; and a view from those who run it. To understand public attitudes, the research team commissioned Ipsos UK to conduct an online survey of over 5,000 adults in the UK and interviewed more than 100 leaders across government and public services.1 This year’s report finds a public sector grappling with an accumulation of successive crises, reduced spending power, increases in demand and workforce challenges with a growing clamour for greater prioritisation. Since its launch, the NHS and social care have featured regularly as two of the public’s top concerns; this year’s report is no different. This blog focuses on the report’s specific findings on health and social care.
By Márcia Costa and Emily May, managers in the Deloitte Centre for Health Solutions
Viruses tend to have a bad reputation. The recent COVID-19 pandemic did not do them any favours and every winter, when flu and norovirus cases soar, we have an unavoidable reminder of the risk viruses pose and just how dangerous they can be. The word virus itself is derived from the Latin word poison. However, viruses are not always against us. In fact, we graciously host a wide variety of them, primarily in our gut, forming part of the body’s microbiome which is crucial in safeguarding our health. Other viruses can help in diagnosing and treating cancer and bacterial infections and improve our understanding of other diseases. In this blog, we explore the nature of viruses and their use in our lives to shine a positive light on these often underappreciated benefits viruses bring.1
By Karen Taylor, Director of the Deloitte Centre for Health Solutions
In our recent report on the Future of Health (FoH) in Europe, we highlight the complex challenges faced by healthcare systems and the actions that are needed by all stakeholders to create more sustainable, equitable and cost-effective services.1 We contend that, by 2040, or sooner in some countries, healthcare will be radically different and will deliver better outcomes for all. The 2024 Global Health Care Sector Outlook launched by our colleagues in the Deloitte Global team, shows that many of the drivers needed to realise the FoH are already happening. This week’s blog provides an overview of the 2024 Outlook report and the five key trends that are shaping the more immediate future of healthcare delivery, and which have the potential to accelerate Deloitte’s FoH vision.
By Andrew Bolt, principal, and Amy Cheung, principal, Deloitte Consulting LLP
For this week’s blog, we have repurposed a blog that was originally published by our colleagues in the US Deloitte Center for Health Solutions in December 2023, exploring the potential for generative artificial intelligence (AI) to accelerate clinical development.1 We identified the potential of AI to transform the traditional linear and sequential clinical trial process in a report we published in February 2020 (Artificial Intelligence in Clinical Trials), but as demonstrated in the US blog, the use of generative AI offers the prospect of even greater improvements, such as accelerating decision making.2 This in turn can reduce clinical development cycle times and further reduce the costs and burden of clinical development. Importantly, when it comes to clinical trials saving time translates to saving lives, or at least improving them, through faster availability of treatments.
By Owen Inglis-Humphrey, Senior Manager and Matt Sands, Manager, Deloitte
One of the first principles taught to clinicians in training is ‘first, do no harm’, instilling the importance of delivering the best care they can for patients. Scan4Safety is an initiative designed to enhance patient safety and improve operational efficiency. By using a simple barcode and GS1 unique identifiers, it enables accurate tracking of products, people, locations and assets throughout the healthcare system. This initiative supports clinicians to deliver the best care by ensuring the right treatments are delivered to the right patients at the right time, while streamlining inventory management and unlocking financial benefits. In this week’s blog, we explore the importance and benefits of Scan4Safety across the NHS, using our experience of large-scale transformations to identify the business change necessary to be successful.
By Naveed Panjwani, Director, and Cian Fahy, Senior Consultant, Deloitte
Deloitte’s annual report series, ‘Measuring the return from pharmaceutical innovation’ has demonstrated that the cost of conducting clinical trials has, on average, increased year-on-year and, for the most part, the average returns that pharma companies can expect to realise from this investment have declined.1 As global pharmaceutical companies increasingly focus on streamlining and reducing the associated costs and timelines of the clinical development pathway, they have largely focused on actions to reduce the more expensive late-stage processes. In this week’s blog we discuss some of the opportunities for improvements across the earlier stages of the clinical trial process.
Márcia Costa, Research Manager and Karen Taylor, Director, Deloitte Centre for Health Solutions
Universal Health Coverage (UHC) means ‘all people have access to the full range of quality health services they need, when and where they need them, without financial hardship’. Yet today, half the world’s population still does not have access to essential health services and two billion people face financial hardship or are impoverished due to out-of-pocket health spending.1 UHC Day on 12 December is an official United Nations (UN) day, marking the UN’s unanimous endorsement of UHC in 2012. UHC was subsequently included as a Sustainable Development Goal (SDG) in 2015 making it a major goal of health system reform.2 All countries reaffirmed this commitment at the UN’s General Assembly on UHC in 2019.3 While progress in achieving the UHC SDG was faltering before the COVID-19 pandemic, progress has since stalled. This year’s UHC Day campaign, Health for All, Time for action, is calling for specific actions to invest in building health system resilience.4 In this blog, we explore the progress on delivering UHC and the steps needed to help deliver the UHC SDG by 2030.